(Bloomberg) -- Eli Lilly & Co. expects to start selling its highly popular weight-loss drug in Hong Kong as early as the end ...

US pharmaceutical company Eli Lilly brings Memory Cafe to its booth at the ongoing 7th CIIE in collaboration with the ...

Eli Lilly logo is shown on one of the company's ... The new investment, which will bring the company's cumulative investment in China to exceed 20 billion yuan ($2.81 billion), aims to boost ...

The latest celebrity weight-loss drug to be given the nod in Hong Kong will be available in December, but experts cautioned ...

opening two research centers called the Eli Lilly China Medical Innovation Center and Lilly Gateway Labs. The newest Gateway Lab is the second to set up shop outside of the U.S. following a ...

Eli Lilly is making a series of investments in China to support its manufacturing and R&D operations. Gilead Sciences has abandoned a liver disease collaboration with Yuhan. A new study suggests ...

Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the third quarter, even as both medicines have largely recovered from ...

Yet, Eli Lilly's GLP-1 medications are helping it compete ... A few months later, Wegovy was approved to enter yet another market: China, a geographic region where obesity rates are quite high.